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Cocirculation of
Dengue Serotypes,
Delhi, India, 2003 
To the Editor: Delhi, in the north-
ern part of India, has had outbreaks of
dengue caused by various dengue
virus types in 1967, 1970, 1982, 1988,
and 1996 (1–5). In 1988, for the first
time, a few cases of dengue hemor-
rhagic fever (DHF) were seen (4).
Subsequently, we reported the largest
outbreak of DHF/dengue shock syn-
drome (DSS) in Delhi in 1996 and
confirmed dengue virus type 2 as the
etiologic agent (5). 
We report the results of virologic
testing of samples received at the All
India Institute of Medical Sciences
from patients with suspected dengue
fever or denguelike illness from Delhi
and its adjoining areas during a 2003
outbreak of dengue. According to the
World Health Organization (6), 2,185
laboratory-confirmed cases were
reported during this outbreak. 
Of the blood samples received by
the virology laboratory, 42 were
received on ice from patients with
acute denguelike illness. Serum was
separated aseptically and stored at
–70°C. The standard method of virus
cultivation, which used the C6/36
clone of the Aedes albopictus cell line,
was followed with some modifications
(7). On days 5 and 10, harvested cells
were tested by an indirect immunoflu-
orescence assay (IFA) using mono-
clonal antibodies to dengue virus types
1–4 (provided by the Centers for
Disease Control and Prevention,
Atlanta, Georgia, USA, during the
1996 outbreak). If IFA results were
negative for dengue viruses on first
passage, a second passage was made,
and cells were again harvested on days
5 and 10 for IFA. The 4 dengue virus
types (obtained from the National
Institute of Virology, Pune, India)
were included as positive controls, and
uninfected C6/36 cells were kept as
negative controls. 
Dengue virus could be isolated in
C6/36 cells from 8 (19%) of 42 sam-
ples processed for virus isolation
(Table). Of the 8 isolates, two each
were identified as dengue virus types
1 and 2, three as type 3, and one as
type 4. All but one isolate were from
patients with uncomplicated dengue
fever. One dengue type 2 isolate was
obtained from a 7-year-old boy with
secondary dengue infection and
DHF/DSS. The ages of culture-posi-
tive patients ranged from 5 to 62
years, with a median of 22 years.
These patients were equally distrib-
uted between children (<12 years) and
adults. The male-to-female ratio for
these 8 patients was 5:3. The duration
of fever at the time of viral isolation
was 1–5 days, with a median of 3
days. 
All previous outbreaks in Delhi
have occurred during the monsoon
(rainy) season between August and
November and subsided with the
onset of winter. We recently reported
the results of serologic testing during
the 2003 outbreak, which also
occurred from September to
November, with a peak in mid-
October 2003 (8). This outbreak was
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milder than the 1996 outbreak, with
less illness and death; most patients
had uncomplicated dengue fever, and
only a few had DHF/DSS. Of the 874
serum samples that we tested, 456
(52.3%) were positive for dengue-
specific immunoglobulin M antibod-
ies by enzyme-linked immunosorbent
assay (Panbio, Sinnamon Park,
Queensland, Australia), and more
than one third of these were from
patients in the 21- to 30-year age
group (8).
Dengue virus types 1, 2, and 3
have all been isolated during previous
dengue outbreaks in Delhi, but a par-
ticular type has always predominated.
During the 1996 outbreak of
DHF/DSS, we had 26 isolates of
dengue virus type 2, but only 1 isolate
was identified as dengue type 1 (5).
However, we subsequently showed
that dengue virus type 1 continued to
circulate during the postepidemic
period and became the predominant
strain (9). Dengue virus type 3 has
recently reemerged in South Asia,
including north India (10). We now
report this culture-confirmed outbreak
of dengue from Delhi, during which
the simultaneous transmission of all 4
dengue virus types has been demon-
strated for the first time in India, with
no particular type predominating.
This finding suggests that dengue is
now truly endemic in this region.
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Borrelia burgdorferi
and Anaplasma
phagocytophilum
Coinfection 
To the Editor: In central Europe,
Anaplasma phagocytophilum and
Borrelia burgdorferi are transmitted
by the hard tick Ixodes ricinus (1).
Acute human granulocytic ehrlichio-
sis (HGE) caused by A. phagocy-
tophilum has rarely been documented
in Europe (2). Typical symptoms
include fever, headache, myalgia,
leukopenia, thrombocytopenia, and
abnormal liver function test results.
The serologic prevalence ranges from
1.9% to 14% in Germany (1), while
clinically apparent infections of HGE
have not been reported. 
Acute Lyme borreliosis in Europe
is associated with erythema migrans
(3), recognized in up to 90% of
patients (4). Erythema migrans may
be accompanied by systemic symp-
toms such as fever, fatigue, myalgia,
arthralgia, headache, or stiff neck
(3,4). In southern Germany, an inci-
dence of 111 per 100,000 inhabitants
has been reported (4).
A 60-year-old woman from north-
ern Germany was admitted with tem-
perature of <40°C, headache, myal-
gia, and generalized weakness that
had begun 6 days earlier. She had
noticed an erythema migrans on her
right thigh 4 days before she sought
treatment. At admission, a tender,
5 × 8 cm rash and a central papule
were seen, but without central clear-
ing. The clinical examination was oth-
erwise normal. Three weeks earlier
she had been on a trekking tour in
Austria and Slovenia but had not been
aware of any tick bites. 
The leukocyte count was 3,030/µL
(normal 4,000–9,000), with 65% neu-
trophils, 24% lymphocytes, 10%
monocytes, and 1% lymphoid cells.
The following results were observed:
platelets 127,000/µL (normal 150,000–
450,000), aspartate aminotransferase
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